Related Experiment Videos
Pharmacokinetics of dexamethasone following single-dose intravenous administration to extremely low birth weight
1Department of Pharmacy, University of Queensland, St. Lucia, Australia.
Insights
Extremely low birth weight infants showed significantly slower dexamethasone clearance and longer half-life compared to older patients. These findings are crucial for optimizing dexamethasone dosing in neonates with bronchopulmonary dysplasia.
Area of Science:
- Pharmacology
- Neonatal Medicine
- Pediatric Critical Care
Background:
- Bronchopulmonary dysplasia (BPD) is a common complication in extremely low birth weight (ELBW) infants.
- Dexamethasone is used to treat BPD, but its pharmacokinetics in ELBW infants are not well-established.
- Understanding drug metabolism in neonates is critical for safe and effective treatment.
Purpose of the Study:
- To characterize the single-dose pharmacokinetics of dexamethasone in ELBW infants with BPD.
- To compare these pharmacokinetic parameters with those reported in pediatric and adult populations.
- To provide data that can inform optimal dexamethasone dosing strategies for this vulnerable population.
Main Methods:
- Single intravenous bolus dose of dexamethasone sodium phosphate administered to 7 ELBW infants (gestational age 25.6 +/- 0.5 weeks) with BPD.
- Plasma dexamethasone concentrations measured using High-Performance Liquid Chromatography (HPLC).
- Pharmacokinetic parameters including peak concentration, clearance, half-life, and volume of distribution calculated.
Main Results:
- Mean peak plasma dexamethasone concentration was 250.5 +/- 70.7 ng/ml.
- Mean clearance (0.143 +/- 0.028 L/kg/h) was approximately half that of children and adults.
- Mean half-life (9.26 +/- 3.34 h) was 2- to 3-fold longer than in older populations.
- Volume of distribution (1.9 +/- 0.483 L/kg) was larger than in adults but similar to pediatric/adult values in another study.
Conclusions:
- ELBW infants exhibit significantly reduced dexamethasone clearance and prolonged half-life compared to older individuals.
- These altered pharmacokinetic parameters suggest a need for adjusted dexamethasone dosing in ELBW infants to avoid potential toxicity or ensure efficacy.
- Further research is warranted to establish optimal dosing regimens for dexamethasone in neonates with BPD based on these findings.
Abstract:
The single-dose pharmacokinetics of dexamethasone were studied in 7 extremely low birth weight infants of mean (+/- SD) gestational age 25.6 +/- 0.5 weeks suffering bronchopulmonary dysplasia. A mean peak dexamethasone concentration of 250.5 +/- 70.7 ng/ml was obtained following an intravenous bolus dose (0.369 +/- 0.04 mg/kg dexamethasone) of dexamethasone sodium phosphate. Dexamethasone was measured in plasma by HPLC. Mean clearance (0.143 +/- 0.028 litres/kg/h) was approximately half that reported previously in children and adults, while the half-life (9.26 +/- 3.34 h) was 2- to 3-fold longer than in these patients. The volume of distribution (1.9 +/- 0.483 litres/kg) was larger than reported in a previous study in adults, but was similar to that determined in pediatric and adult patients in another study.